Although synthesizing and investigating a first-in-class new agent for EWS will be challenging, such an approach may have applications beyond EWS, given that the EWS and ETS fusion transcripts occur in other sarcomas including desmoplastic small blue round cell tumor (EWS-WTI), myxoid liposarcoma (EWS-CHOP), clear-cell sarcoma (EWS-AFT1), chondrosarcoma (EWS-TEC), and angiomatoid fibrous histiocytoma (EWSR1-ATF1) as well as several other nonsarcomatous cancers including acute myeloid leukemia (TLS-ERG), secretory breast carcinoma (ETV6-NTRK3), and prostate cancer (TMPRSS2-ERG). Here, ERG is linked to clear cell sarcoma.